Endocrine-Related Cancer

Endocrine-Related Cancer. RET@Thirty: Three Decades of Remarkable Progress. Special Collection.

Marking 30 years, the RET@Thirty Special Collection features an exclusive editorial with Professor Sir Bruce Ponder & brings together mini-reviews addressing the multifaceted aspects of RET & its impact on clinical practice.

Explore the collection: erc.bioscientifica.com/page/RET@Thirty

Endocrine-Related Cancer logo. Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms. By Blanca R Carranza-Zavala et al. Figure 1. Initial assessment of AIP variants in the study cohort. (A) Coronal (left) and sagittal (right) representative gadolinium-enhanced T1-weighted preoperatory magnetic resonance images of Case 3, showing a pituitary macroadenoma. (B) Frequency of AIP variants within each clinical category included in the cohort of adult patients with NENs. (C) Schematic representation of AIP exons (top) and corresponding protein domains (bottom) displaying the VOI identified in this study. α-helix, carboxy-terminal alpha-helix; CS, Cushing’s syndrome; EO, early onset; GH, growth hormone; LB, likely benign; MEN, multiple endocrine neoplasia; MEN1, MEN type 1; MEN2A and MEN2B, MEN types 2A and 2B; MTC, medullary thyroid carcinoma; NENs, neuroendocrine neoplasms; NF1, neurofibromatosis type 1; P/LP, pathogenic and likely pathogenic; PanNEN, pancreatic neuroendocrine tumor; PHPT, primary hyperparathyroidism; PitNET, pituitary neuroendocrine tumor; PPGL, pheochromocytoma or paraganglioma; PPIase, peptidyl-prolyl cis–trans isomerase domain; TPR1, TPR2, and TPR3, tetratricopeptide repeats 1, 2, and 3; VHL, von Hippel–Lindau syndrome; VOI, variants of interest; VUS, variant of uncertain significance. Citation: Endocrine-Related Cancer 33, 1; 10.1530/ERC-25-0095. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.

Could AIP loss-of-function contribute to neuroendocrine neoplasms (NENs) beyond pituitary tumours?

Blanca R Carranza-Zavala et al. investigated the prevalence and in‑vitro effects of germline AIP variants in Mexican patients with NENs.

🔓 Full research #OpenAccess: doi.org/10.1530/ERC-25-0095

Endocrine-Related Cancer logo. Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A. By Marijn L van den Berg et al. Figure 2. Postoperative calcitonin course during follow-up presented for each individual patient. Ctn, calcitonin; TTx, thyroidectomy; MTC, medullary thyroid cancer; ULN, upper limit of normal. Endocrine-Related Cancer 33, 1; 10.1530/ERC-25-0366. Published by Bioscientifica logo. 80 Years 1946-2026 Society for Endocrinology logo.

A new study by Marijn L van den Berg et al. analyses long‑term calcitonin trends in 52 MEN2A patients after total thyroidectomy, revealing distinct postoperative patterns that could inform more personalised surveillance.

🔓 Read the full article: doi.org/10.1530/ERC-25-0366

Emerging Leaders 2025 Special Collection. Explore the 2025 Emerging Leaders Collection.

🌟 We take pride in our annual Emerging Leaders Special Collection, celebrating the knowledge & talent of exceptional early‑career scientists shaping the future of the field.

Explore the researchers and articles featured in our 2025 collection: erc.bioscientifica.com/page/emerging-leaders-2025

Endocrine-Related Cancer logo. 80 Years Society for Endocrinology logo. PDF screenshot of 'Expanding horizons in Endocrine-Related Cancer: innovation, imagination, and a shared global vision' (https://doi.org/10.1530/ERC-25-0497)

🚀 The new year marks an exciting transition for Endocrine-Related Cancer as Prof. Karel Pacak begins his term as Editor-in-Chief!

In a new editorial, Prof. Pacak outlines 5 principles that will guide the journal as a platform for collaboration, inspiration & progress: doi.org/10.1530/ERC-25-0497

Systems Biology Approaches in Hormone-Dependent Cancer Research. Themed Collection. Endocrine-Related Cancer logo. New Review: Hallmarks of disease: how tuned hierarchies of intelligent molecular neural networks (MNNs) may matter. By Hans V Westerhoff.

A new review by Hans V. Westerhoff explores how complexity, plasticity and circular causality make intracellular networks resemble trained neural networks. Comparing disease challenges with those in evolution or development may reveal 'learned' cellular responses.

🔗 doi.org/10.1530/ERC-25-0183

Endocrine-Related Cancer logo. New Associate Editor. Ilan Shimon, MD Head of the Endocrinology & Diabetes Institute at Rabin Medical Centre and Professor of Medicine at Tel Aviv University, Israel Society for Endocrinology logo.

We are delighted to welcome Professor Ilan Shimon, MD, as a new Associate Editor for Endocrine‑Related Cancer.

A leading clinical academic endocrinologist and former ENEA President, he brings extensive expertise in pituitary tumour research.

🔗 erc.bioscientifica.com

Endocrine-Related Cancer logo. New Research. Predictors of survival outcomes in patients with neuroendocrine neoplasms: a real-world retrospective study. By Marta Laganà et al. Published by Bioscientifica. Society for Endocrinology logo.

📊 Real-world survival outcomes in neuroendocrine neoplasms (NENs)

A retrospective study by Marta Laganà et al. analysed 239 patients with NENs (2010–2023), reporting overall survival (OS), progression-free survival (PFS), and key predictors.

Read the article: doi.org/10.1530/ERC-25-0243

Endocrine-Related Cancer logo. New Research: GLP1 receptor agonism alters growth and therapeutic response in prostate cancer. By Soumen Bera et al. Published by Bioscientifica logo. Society for Endocrinology logo.

New research by Soumen Bera et al. supports a model where GLP1R agonism blocks oncogenic pathways and growth of prostate cancer cells, pointing to potential therapeutic applications of semaglutide in advanced prostate cancer.

👉 Read the article: doi.org/10.1530/ERC-25-0185

Collection Curated by Prof. Karel Pacak. Incoming Editor-in-Chief of Endocrine-Related Cancer. Images of PDFs of a selection of the selected articles. Endocrine-Related Cancer logo.

⭐ Which articles are shaping the conversation in endocrine oncology?

Our incoming Editor‑in‑Chief, Professor Karel Pacak, has curated his first Editors’ Choice Collection.

📚 Explore the collection: erc.bioscientifica.com/page/edchoice/editors-choice

Endocrine-Related Cancer logo. New Review: Towards harmonised paediatric thyroid cancer care: adult comparisons and gaps. By Michaela Kuhlen, Marina Kunstreich, and Antje Redlich. Published by bioscientifica logo. Society for Endocrinology logo.

A new narrative review by Michaela Kuhlen, Marina Kunstreich and Antje Redlich explores how paediatric and adult DTC differ across biology, presentation, treatment strategies and guidelines, highlighting the need for harmonised, age‑specific approaches.

doi.org/10.1530/ERC-25-0191

Top left: Endocrine-Related Cancer logo. Text: Explore and contribute to expert-curated research on hormone-related cancers. Bottom right: Society for Endocrinology logo.

Spotlighting our latest completed collections & our open collections for submissions.

✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀:
🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY
🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs

💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀:
🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7
🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6

Headline text: Welcome our new Associate Editor... Headshot of Joakim Crona, MD, PhD Text reads: Joakim Crona, MD, PhD, Associate Professor, Uppsala University, Sweden Bottom left: Endocrine-Related Cancer logo. Bottom right: Society for Endocrinology logo.

Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.

Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀

Endocrine-Related Cancer. 2025 Best Paper Award. Bioscientifica. Society for Endocrinology.

🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.

Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!

Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.

At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.

🔗 lnkd.in/eBY6uA_r

#WorldNeuroendocrineCancerDay

Special Collection. Advances and Innovation: The Next Chapter in Pheochromocytoma and Paraganglioma. Endocrine-Related Cancer.

We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.

🔗 For more info: lnkd.in/d3gyVVbg

Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix

🎉 Excited to share our new publication!

Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.

Potential therapeutic strategy for aggressive PNENs?

bit.ly/435pKBx

@endocancer.bsky.social

New Research: First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context in Endocrine-Related Cancer. By Vincenzo Marotta et al. Published by Bioscientifica. Society for Endocrinology.

Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.

Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.

Subscribers can read the article: doi.org/10.1530/ERC-24-0215

New Research: Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer in Endocrine-Related Cancer. By Takayuki Ueno et al. Figure 1. Study flow diagram. Citation: Endocrine-Related Cancer 32, 9; 10.1530/ERC-24-0353

🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.

Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353

Endocrine-Related Cancer. Exciting opportunity to join our Editorial Board. "The programme allowed me to dip my toes into the editorial side of peer review, to which I had not previously been exposed." Amy Dwyer, PhD. Current Endocrine-Related Cancer Early-Career Editor. Society for Endocrinology.

Early-Career Editor Opening!

A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.

To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.

Questions? Reach out to erc@bioscientifica.com

NEW RESEARCH: Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers in Endocrine-Related Cancer. By Di Sun et al. Published by Bioscientifica. Society for Endocrinology.

New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.

🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027

Locoregional progression and surgical indications in stage IV asymptomatic SI-NETs in Endocrine-Related Cancer. By Branislav Klimácek et al. Figure 2. Kaplan−Meier estimates of time to symptom onset in initially asymptomatic patients. A full color version of this figure is available at https://doi.org/10.1530/ERC-25-0205. Citation: Endocrine-Related Cancer 32, 8; 10.1530/ERC-25-0205 Published by Bioscientifica. Society for Endocrinology.

New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.

Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205

Register Now! 2025 Margie & Robert E. Petersen. Neuroendocrine Tumor Research Symposium. Breakthroughs today, cures tomorrow. Location: Boston, Massachusetts. Date: November 17-19.

Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.

The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.

Register now: bit.ly/4nQ9goU

#NETresearch #cancerresearch

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer | OncLive Neoadjuvant palbociclib plus endocrine therapy did not improved PEPI scores in operable hormone receptor–positive breast cancer.

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...

Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more.
Explore the collection: erc.bioscientifica.com/page/PPGL

New Research: Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer in Endocrine-Related Cancer. By Vikki L Poole et al. Published by Bioscientifica. Society for Endocrinology. Figure 1. Phosphorylated PBF represses RAIU in breast cancer cells. (A) Left – schematic of the interaction between NIS and PBF proteins tagged at the C-terminus with the NanoLuc luciferase subunits LgBiT and SmBiT, respectively. In close proximity, LgBiT and SmBiT form a functional enzyme that uses the substrate furimazine to produce a high-intensity, luminescent signal. Created using Alphafold (59, 60) and BioRender. Right – NanoBiT analysis of NIS:PBF interaction in MCF-7 cells, with bar graph showing results at 20 min post-addition of Nano-Glo live cell assay substrate. (B) Co-immunoprecipitation assay showing PBF-HA and NIS-MYC interaction in MCF-7 breast cancer cells. (C) Schematic of PBF highlighting the overlapping phosphorylation site and endocytosis motif at the C-terminus, and the PBF-Y174A and E170_N172delinsAAA (PBF-EEN MUT) mutants. (D) Western blot showing the phosphorylation status of PBF-Y174A and PBF-EEN MUT compared with PBF-WT in MCF-7 cells. (E) Immunofluorescent images showing PBF-WT, PBF-Y174A and PBF-EEN MUT localisation in MCF-7 cells. (F) Immunofluorescent images showing subcellular localisation following the co-transfection of NIS-MYC (green) with VO, PBF-WT, PBF-Y174A or PBF-EEN MUT (red) in MCF-7 cells. Co-localisation is seen in yellow. (G) The effect of PBF and phosphomutants (Y174A/EEN-MUT) on RAIU in MCF-7 (i) and MDA-MB-231 (ii) cells transiently co-transfected with NIS-MYC. (H) The effect of PBF and phosphomutants (Y174A/EEN-MUT) on RAIU in MCF-7 cells treated with ATRA and dexamethasone. VO = vector only control. Bars = 10 μm. n = 3 for all experiments. Error bars = SEM. Significance shown compared with VO unless otherwise shown...Endocrine-Related Cancer 32, 8; 10.1530/ERC-24-0312

🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.

Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.

Read #OpenAccess: doi.org/10.1530/ERC-...

New Research: Heme-oxygenase-1: a key player in thyroid carcinoma development in Endocrine-Related Cancer. By Exequiel Gonzalo Alonso et al. Graphical Abstract. Published by Bioscientifica. Society for Endocrinology.

New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎

🎯Could HO-1 be a therapeutic target?

Subscribers can read the research: doi.org/10.1530/ERC-25-0177

#ThyroidCancer #CancerResearch

Special Collection: Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms. Endocrine-Related Cancer. Collection Editors: Dr. Sunita M. C. De Sousa, MD, PhD Dr. Frederic Castinetti, MD, PhD Dr. Henriett Butz, MD, PhD Dr. Adrian F. Daly, MD, PhD

🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!

We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.

📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc

Targeting RET in medullary thyroid cancer in Endocrine-Related Cancer. By Kate Newbold and Leslie Cheng. This paper forms part of the themed collection RET@Thirty: Three Decades of Remarkable Progress. The Guest Editors for this collection were Tom Kurzawinski, Neil McDonald and Kate Newbold.

🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.

A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.

🔗 doi.org/10.1530/ERC-24-0291

Follow us on LinkedIn. LinkedIn logo. Endocrine-Related Cancer logo.

🌱Endocrine-Related Cancer is officially on LinkedIn!

Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.

🌐 linkedin.com/company/endocrine-related-cancer/

#MedSky #CancerResearch #EndocrineOncology #HormoneCancers